BR9908540A - Molécula de ácido nucleico recombinante, célula hospedeira recombinante, composição farmacêutica, e, processo para induzir uma resposta imune contra vìrus de hepatite c em um humano não infectado por vìrus de hepatite c, para imunizar um humano suscetìvel a vìrus de hepatite c, e para tratar um humano que é infectado com vìrus de hepatite c - Google Patents

Molécula de ácido nucleico recombinante, célula hospedeira recombinante, composição farmacêutica, e, processo para induzir uma resposta imune contra vìrus de hepatite c em um humano não infectado por vìrus de hepatite c, para imunizar um humano suscetìvel a vìrus de hepatite c, e para tratar um humano que é infectado com vìrus de hepatite c

Info

Publication number
BR9908540A
BR9908540A BR9908540-2A BR9908540A BR9908540A BR 9908540 A BR9908540 A BR 9908540A BR 9908540 A BR9908540 A BR 9908540A BR 9908540 A BR9908540 A BR 9908540A
Authority
BR
Brazil
Prior art keywords
hepatitis
virus
human
infected
nucleic acid
Prior art date
Application number
BR9908540-2A
Other languages
English (en)
Inventor
Jack Wands
Jens Encke
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Publication of BR9908540A publication Critical patent/BR9908540A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"MOLéCULA DE áCIDO NUCLEICO RECOMBINANTE, CéLULA HOSPEDEIRA RECOMBINANTE, COMPOSIçãO FARMACêUTICA, E, PROCESSOS PARA INDUZIR UMA RESPOSTA IMUNE CONTRA VìRUS DE HEPATITE C EM UM HUMANO NãO INFECTADO POR VìRUS DE HEPATITE C, PARA IMUNIZAR UM HUMANO SUSCETìVEL A VìRUS DE HEPATITE C, E PARA TRATAR UM HUMANO QUE é INFECTADO COM VìRUS DE HEPATITE C". Moléculas de ácido nucleico que compreende uma proteína não estrutural de hepatite C incluindo seq³ências de DNA especificamente descritas são descritas. As composições farmacêuticas que contém moléculas de ácido nucleico compreendendo uma proteína não estrutural de hepatite C incluindo uma seq³ência de nucleotídeos codificando NS3, NS4 E NS5, ou uma combinação dos mesmos, ligada de modo operativo a elementos regulatórios funcionais em células humanas são descritas. Processo para imunizar indivíduos suscetíveis a ou infectados por vírus de hepatite C compreendendo a administração destas composições farmacêuticas são descritos.
BR9908540-2A 1998-01-30 1999-01-28 Molécula de ácido nucleico recombinante, célula hospedeira recombinante, composição farmacêutica, e, processo para induzir uma resposta imune contra vìrus de hepatite c em um humano não infectado por vìrus de hepatite c, para imunizar um humano suscetìvel a vìrus de hepatite c, e para tratar um humano que é infectado com vìrus de hepatite c BR9908540A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7315698P 1998-01-30 1998-01-30
PCT/US1999/001823 WO1999038880A1 (en) 1998-01-30 1999-01-28 Genetic immunization with nonstructural proteins of hepatitis c virus

Publications (1)

Publication Number Publication Date
BR9908540A true BR9908540A (pt) 2000-11-28

Family

ID=22112053

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9908540-2A BR9908540A (pt) 1998-01-30 1999-01-28 Molécula de ácido nucleico recombinante, célula hospedeira recombinante, composição farmacêutica, e, processo para induzir uma resposta imune contra vìrus de hepatite c em um humano não infectado por vìrus de hepatite c, para imunizar um humano suscetìvel a vìrus de hepatite c, e para tratar um humano que é infectado com vìrus de hepatite c

Country Status (9)

Country Link
EP (1) EP1056762A4 (pt)
JP (1) JP2002501737A (pt)
KR (2) KR20060057653A (pt)
CN (3) CN101126095A (pt)
AU (1) AU746258B2 (pt)
BR (1) BR9908540A (pt)
CA (1) CA2318744A1 (pt)
IL (1) IL137458A0 (pt)
WO (1) WO1999038880A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1232267B1 (en) * 1999-10-27 2013-03-20 Novartis Vaccines and Diagnostics, Inc. Activation of hcv-specific t cells
CN101684146A (zh) * 1999-11-24 2010-03-31 诺华疫苗和诊断公司 新颖的hcv非结构多肽
US6986892B1 (en) 1999-11-24 2006-01-17 Chiron Corporation Immunogenic Hepatitis C virus non-structural polypeptides
CA2461380C (en) 2001-10-11 2011-03-22 Merck & Co., Inc. Hepatitis c virus vaccine
FR2855758B1 (fr) 2003-06-05 2005-07-22 Biomerieux Sa Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
KR101679731B1 (ko) * 2011-10-24 2016-11-25 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 hcv 백신 및 이것을 사용하는 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2079105C (en) * 1990-04-04 2000-06-13 Michael Houghton Hepatitis c virus protease
WO1994016737A1 (en) * 1993-01-26 1994-08-04 Weiner David B Compositions and methods for delivery of genetic material
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
AU5924396A (en) * 1995-05-22 1996-12-11 Bionova Corporation Compositions and methods for the diagnosis of, and vaccinati on against, hepatitis c virus (hcv)
EP0935662B1 (en) * 1996-05-24 2005-11-30 Chiron Corporation Multiple epitope fusion protein
CA2257137A1 (en) * 1996-06-11 1997-12-18 Merck & Co., Inc. Synthetic hepatitis c genes
DE69838513T2 (de) * 1997-12-11 2008-07-03 Smithkline Beecham Corp. Verkürztes hepatitis-c-virus protein nsb5 und methoden, um antivirale substanzen zu identifizieren

Also Published As

Publication number Publication date
AU746258B2 (en) 2002-04-18
CN101126094A (zh) 2008-02-20
KR100628411B1 (ko) 2006-09-28
KR20060057653A (ko) 2006-05-26
EP1056762A1 (en) 2000-12-06
CN100335637C (zh) 2007-09-05
JP2002501737A (ja) 2002-01-22
CA2318744A1 (en) 1999-08-05
IL137458A0 (en) 2001-07-24
CN1289339A (zh) 2001-03-28
CN101126095A (zh) 2008-02-20
KR20010086226A (ko) 2001-09-10
WO1999038880A1 (en) 1999-08-05
EP1056762A4 (en) 2003-07-23
AU2478699A (en) 1999-08-16

Similar Documents

Publication Publication Date Title
Sizova et al. Specific interaction of eukaryotic translation initiation factor 3 with the 5′ nontranslated regions of hepatitis C virus and classical swine fever virus RNAs
Srivastava et al. A purified inactivated Japanese encephalitis virus vaccine made in Vero cells
Takada et al. Differences in the hepatitis C virus genotypes in different countries
Kurosaki et al. Rapid sequence variation of the hypervariable region of hepatitis C virus during the course of chronic infection
BR0111956A (pt) Tratamento do vìrus do papiloma humano
BR0007414A (pt) Expressão e exportação de proteìnas antiobesidade como proteìnas de fusão fc
BR0010725A (pt) Expressão e exportação de proteìnas de interferon-alfa como proteìnas de fusão de fc
BRPI0511196A (pt) polipeptìdeo isolado ou recombinante, conjugado, composição, célula hospedeira, vetor, métodos para preparar um polipeptìdeo, para preparar um conjugado, para reduzir o número de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna hcv, dna hbv e rna hiv no soro de um paciente infectado com hcv, hbv e hiv, e, uso do polipeptìdeo, do conjugado ou da composição
FR2711670B1 (fr) Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
BR0213103A (pt) Método para tratamento de infecção pelo vìrus da hepatite com um perfil de liberação de interferon multifásico
DE602005026545D1 (de) Modifizierte genomische rna des menschlichen hepatitis-c-virus mit autonomer replikationskompetenz
KR900013984A (ko) 항-바이러스 치료를 위한 세포간 점착 분자 icam-1의 작용성 유도체의 용도
Chin et al. Virucidal short wavelength ultraviolet light treatment of plasma and factor VIII concentrate: protection of proteins by antioxidants
Squadrito et al. Long-term response to interferon alpha is unrelated to “interferon sensitivity determining region” variability in patients with chronic hepatitis C virus-1b infection
Glass et al. Identification of a trans-acting activity from liver that stimulates hepatitis A virus translation in vitro
CA2331368A1 (en) Nucleic acid vaccines for prevention of flavivirus infection
MXPA05005203A (es) Vacuna contra vhc.
Alt et al. Core specific antisense phosphorothioate oligodeoxynucleotides as potent and specific inhibitors of hepatitis C viral translation
Soler et al. Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment
BR9908540A (pt) Molécula de ácido nucleico recombinante, célula hospedeira recombinante, composição farmacêutica, e, processo para induzir uma resposta imune contra vìrus de hepatite c em um humano não infectado por vìrus de hepatite c, para imunizar um humano suscetìvel a vìrus de hepatite c, e para tratar um humano que é infectado com vìrus de hepatite c
Bittar et al. Genetic diversity of NS5A protein from hepatitis C virus genotype 3a and its relationship to therapy response
HK1130664A1 (en) Hepatitis c virus non structural fusion protein
Heinz et al. Formation of polymeric glycoprotein complexes from a flavivirus: tick-borne encephalitis virus
Rispeter et al. Cloning and characterization of a complete open reading frame of the hepatitis C virus genome in only two cDNA fragments.
ATE430167T1 (de) Humaner rekombinanter antikörper gegen das hepatitis c (hcv) nichtstrukturelles ns3 protein, nukleinsäure und deren verwendungen

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE COMO INVENCAO DE ACORDO COM O ART. 8O DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.